Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of a Nicotinamide Riboside-Based Dietary Supplement on Retinal Function in Glaucoma (BRIGHT) (BRIGHT)

17. november 2026 oppdatert av: Fondazione G.B. Bietti, IRCCS

Boosting Retinal Impulses in Glaucoma With a Holistic Therapeutic Approach: a Randomized, Placebo-controlled, Electrophysiology-based Clinical Trial. The BRIGHT Study

The goal of this clinical trial is to learn whether a daily dietary supplement called iNAD CONTROL can improve the function of the retinal ganglion cells (the nerve cells of the retina that carry visual information to the brain) in adults with open-angle glaucoma who are already being treated with eye-pressure-lowering therapy. iNAD CONTROL contains nicotinamide riboside (a form of vitamin B3), acetyl-L-carnitine, forskolin and hesperidin, which may support the energy metabolism of these nerve cells and protect them from damage.

The main question it aims to answer is:

- Does taking iNAD CONTROL for 12 weeks improve retinal ganglion cell function, measured with an electroretinogram (ERG, a test that records the electrical response of the retina to light), compared with a placebo (a look-alike tablet with no active ingredients)?

Researchers will also look at whether iNAD CONTROL changes the visual field, the thickness of the retinal nerve fiber layers measured with optical coherence tomography (OCT), visual acuity and eye pressure.

Researchers will compare iNAD CONTROL with placebo. Each participant will receive both: iNAD CONTROL for 12 weeks and placebo for 12 weeks, in a random order. Neither the participants nor the study doctors will know which product is being taken in each period.

Participants will:

  • Take 1 tablet a day for 24 weeks in total (12 weeks of iNAD CONTROL and 12 weeks of placebo)
  • Continue their usual glaucoma eye drops without changes
  • Attend 5 clinic visits over 6 months (at the start and at weeks 6, 12, 18 and 24)
  • At each visit, undergo non-invasive eye tests: visual acuity, eye pressure, visual field tests, ERG and OCT, plus blood pressure and body weight measurement

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Detaljert beskrivelse

BACKGROUND Glaucoma is characterized by progressive dysfunction and loss of retinal ganglion cells (RGCs) and their axons. Oxidative stress and mitochondrial dysfunction are increasingly recognized as key mechanisms underlying RGC degeneration. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor for mitochondrial ATP production and for NAD+-dependent enzymes that regulate cellular stress responses and survival. Patients with primary open-angle glaucoma have been shown to have reduced circulating levels of nicotinamide, a major NAD+ precursor, and preclinical studies have shown that raising retinal NAD+ levels protects RGCs and preserves retinal function in experimental glaucoma. Objective electrophysiological measures of inner retinal function, in particular the photopic negative response (PhNR) of the full-field electroretinogram (ERG), can detect short-term changes in RGC-related function and are suitable for interventional studies in which structural or perimetric changes are expected to be modest over a period of months.

RATIONALE This study evaluates RGC function in response to oral supplementation with nicotinamide riboside and acetyl-L-carnitine, compounds that support energy metabolism (direct neuroprotection), combined with forskolin and hesperidin, natural antioxidants that may support IOP-lowering therapy (indirect neuroprotection). Nicotinamide riboside and acetyl-L-carnitine together support the synthesis of acetyl-coenzyme A, and therefore of ATP and acetylcholine, even under the conditions of impaired glycolysis observed in glaucoma. Forskolin and hesperidin may help counteract sudden, transient increases in IOP despite hypotensive therapy. The combination is administered as the dietary supplement iNAD CONTROL.

STUDY DESIGN

Interventional, national, multicentre, prospective, double-masked, randomized, placebo-controlled 2x2 cross-over trial. Sixty adults with treated open-angle glaucoma (mean deviation between -3.0 and -12.0 dB) and stable IOP below 18 mmHg will be enrolled and randomized 1:1 to one of two treatment sequences:

  • Sequence A: iNAD CONTROL for 12 weeks (Period 1), followed by placebo for 12 weeks (Period 2)
  • Sequence B: placebo for 12 weeks (Period 1), followed by iNAD CONTROL for 12 weeks (Period 2) No wash-out period is included, as the supplement is expected to exert reversible biological effects without prolonged carry-over after discontinuation; carry-over and period effects will be assessed statistically.

INTERVENTION iNAD CONTROL, 1 tablet per day orally for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (15 mg forskolin) and micronized hesperidin 50 mg.

Placebo: a food product free of functional ingredients, matched to the study product in appearance and organoleptic characteristics, 1 tablet per day orally for 12 weeks.

Standard glaucoma treatment continues unchanged. Other systemic or topical agents with potential neuroprotective effects (e.g., citicoline) are prohibited during the study.

RANDOMIZATION AND MASKING The randomization list is generated by an independent statistician using a computer-generated schedule with permuted blocks of variable size. Randomization is centralized through the electronic study database and occurs only after eligibility is confirmed at the baseline visit. Participants, investigators, outcome assessors, study coordinators, data managers and statisticians involved in the primary analysis remain masked to treatment allocation. Study products are packaged and labelled identically.

STUDY VISITS AND PROCEDURES Each participant attends 5 visits over 24 weeks: Week 0 (baseline/randomization), Week 6, Week 12 (end of Period 1 and cross-over), Week 18 and Week 24 (end of Period 2/end of study). At every visit the following are performed: best-corrected visual acuity (ETDRS letters or logMAR), slit-lamp biomicroscopy, Goldmann applanation tonometry, blood pressure, body weight, standard automated perimetry, photopic ERG, SD-OCT, adverse event recording, concomitant medication review and pill count for adherence.

  • Perimetry: Humphrey Field Analyzer, 24-2 SITA Standard repeated twice per eye (the mean of the two reliable tests is used) and 10-2 SITA Standard once per eye, in the sequence 24-2, 24-2, 10-2.
  • ERG: handheld RETeval device (LKC Technologies) with skin electrodes after pharmacological pupil dilation and standardized photopic adaptation; photopic full-field ERG with a red flash on a blue background (CD LONG protocol), with harmonized settings across centres. Waveforms are processed centrally by masked assessors. The PhNR peak-to-trough amplitude (PhNRPT, distance in microvolts from the b-wave peak to the trough of the PhNR) is calculated as the mean of 3 consecutive recordings. The W-ratio is calculated as (b-wave amplitude - PhNR trough) / (b-wave amplitude - a-wave amplitude).
  • OCT: circumpapillary RNFL and ganglion cell complex (GCC) thickness (Spectralis SD-OCT, Heidelberg Engineering, or Cirrus HD-OCT, Carl Zeiss Meditec).

One eye per participant is designated as the study eye; if both eyes are eligible, the eye with the better quality visual field at screening is selected.

STATISTICAL ANALYSIS The sample size was informed by a similar cross-over trial of nicotinamide in glaucoma (Hui et al., 2020). Enrolling 60 participants, allowing for approximately 20% attrition or unreliable ERG/visual field measurements, is expected to provide at least 48 evaluable participants and 80% power to detect a clinically meaningful difference in PhNRPT between treatment periods (two-sided alpha 0.05).

The primary analysis set includes participants with outcome data after both treatment periods; a per-protocol analysis includes adherent participants without major protocol deviations. The difference between iNAD CONTROL and placebo in change from baseline in PhNRPT after each 12-week period will be assessed with linear mixed models adjusting for baseline value, period and centre. Prespecified tests for carry-over and period effects will be performed; if clinically important carry-over is detected, a sensitivity analysis using first-period data only will be performed. Missing data will be handled with mixed models under a missing-at-random assumption, with multiple imputation and complete-case sensitivity analyses. Secondary endpoints will be analysed within the same cross-over framework, with multiplicity addressed by a hierarchical approach or emphasis on effect sizes and confidence intervals. An exploratory analysis will assess the effect across disease stages, including both eyes where eligible, with adjustment for inter-eye correlation.

FUNDING The study is sponsored by IRCCS Fondazione G.B. Bietti and partially funded by an unrestricted grant from OFFHEALTH, which also supplies iNAD CONTROL and placebo free of charge and has no role in study design, data collection, analysis, interpretation or publication.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Carmela Carnevale
  • Telefonnummer: 0684009442

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Freely given written informed consent obtained prior to any study procedure
  • Capacity to understand and willingness to follow study instructions, and likely to complete all required visits and procedures
  • Diagnosis of open-angle glaucoma under IOP-lowering treatment
  • Visual field mean deviation (MD) between -3.0 and -12.0 dB
  • Best-corrected visual acuity of 8/10 (0.1 logMAR) or better
  • Spherical refraction between +3 and -4 diopters and astigmatism within ±3 diopters
  • IOP below 18 mmHg at the 2 previous visits and at the screening visit
  • Stable IOP-lowering regimen planned for the next 6 months, as judged by the investigator
  • Reliable Humphrey 24-2 visual field at screening/baseline (fixation losses and false negatives below 15%, false positives below 10%)
  • Reproducible glaucomatous visual field defect, defined as Glaucoma Hemifield Test outside normal limits and a cluster of 3 or more locations on the pattern deviation plot, 2 of which are depressed at P<5% and 1 at P<1%, on at least 2 consecutive reliable fields, with at least 1 common location in the cluster depressed at P<5% in both fields (30-2 or 24-2 tests may be used, considering only the 24-2 locations)
  • At least 3 visual field examinations performed in the 3 years prior to enrollment, to minimize learning effects
  • Women of childbearing potential must agree to use an appropriate contraceptive method and have a negative urine pregnancy test on the first day of dosing

Only one eye per participant is designated as the study eye. If both eyes are eligible, the eye with the better quality visual field at screening (lower fixation losses and false-positive rates) is selected. Ocular inclusion criteria (MD, IOP, visual acuity, refraction, astigmatism) apply to the study eye only; the fellow eye must not meet any exclusion criterion that could confound interpretation of results.

Exclusion Criteria:

  • Intraocular surgery within the previous 6 months, or surgery planned during the study
  • Coexisting retinal or optic nerve disease (e.g., non-glaucomatous optic neuropathies of ischemic, inflammatory or compressive origin), moderate-to-severe diabetic retinopathy, advanced macular degeneration, or advanced cataract likely to confound ERG, visual field or OCT interpretation
  • Use of any other systemic or topical agent with potential neuroprotective effects (e.g., citicoline) within the previous month or planned during the study
  • Changes in IOP-lowering therapy within the previous 3 months
  • Pregnancy or breastfeeding
  • Known allergy to nicotinamide riboside, acetyl-L-carnitine, forskolin, hesperidin or any excipient
  • Clinically significant hepatic disease or active gastrointestinal ulcer disease
  • Severe renal impairment (e.g., eGFR below 30 mL/min/1.73 m²) or other condition judged by the investigator to increase risk
  • History of cancer within the past 5 years

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Sequence A: iNAD CONTROL then Placebo

Participants take iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to matching placebo, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.

Oral dietary supplement, 1 tri-layer tablet once daily for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (equivalent to 15 mg forskolin) and micronized hesperidin 50 mg. Gluten-free and lactose-free. Supplied free of charge by OFFHEALTH.

Oral placebo tablet, 1 tablet once daily for 12 weeks. A food product free of functional ingredients, containing only excipients, matched to iNAD CONTROL in appearance and organoleptic characteristics and packaged identically to maintain masking.

Eksperimentell: Sequence B: Placebo then iNAD CONTROL

Participants take matching placebo, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.

Oral dietary supplement, 1 tri-layer tablet once daily for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (equivalent to 15 mg forskolin) and micronized hesperidin 50 mg. Gluten-free and lactose-free. Supplied free of charge by OFFHEALTH.

Oral placebo tablet, 1 tablet once daily for 12 weeks. A food product free of functional ingredients, containing only excipients, matched to iNAD CONTROL in appearance and organoleptic characteristics and packaged identically to maintain masking.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in PhNR Peak-to-Trough Amplitude (PhNRPT)
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in the photopic negative response peak-to-trough amplitude (PhNRPT), defined as the distance in microvolts from the peak of the b-wave to the trough of the subsequent photopic negative response (PhNR), recorded in the study eye with photopic full-field ERG (RETeval, red flash on blue background, CD LONG protocol) after pupil dilation. The value at each timepoint is the mean of 3 consecutive ERG recordings, processed centrally by masked assessors. Higher values indicate better retinal ganglion cell function.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in ERG b-Wave Amplitude
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in photopic ERG b-wave amplitude (microvolts) in the study eye, recorded with RETeval (red flash on blue background, CD LONG protocol) and processed centrally by masked assessors.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in ERG b-Wave Implicit Time
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in photopic ERG b-wave latency (implicit time, milliseconds) in the study eye.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Photopic Electroretinogram (ERG) W-Ratio
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

The reported outcome is the within-period change in the dimensionless photopic ERG W-ratio in the study eye, calculated as the end-of-period W-ratio minus the start-of-period W-ratio for each 12-week treatment period. At each assessment, a single W-ratio is calculated from the photopic ERG waveform as (b-wave amplitude - PhNR trough) / (b-wave amplitude - a-wave amplitude), where PhNR is the photopic negative response.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in Circumpapillary Retinal Nerve Fiber Layer (RNFL) Thickness and Ganglion Cell Complex (GCC) Thickness
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in global circumpapillary RNFL thickness (micrometers) and macular ganglion cell complex thickness (micrometers) in the study eye, measured with spectral-domain OCT.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Best-Corrected Visual Acuity (BCVA)
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in best-corrected visual acuity in the study eye, measured with ETDRS charts and expressed as logMAR. Lower logMAR values indicate better vision.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Intraocular Pressure (IOP)
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in intraocular pressure (mmHg) in the study eye, measured with Goldmann applanation tonometry.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Mean Arterial Pressure (MAP)
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in mean arterial pressure (mmHg), calculated from systolic and diastolic blood pressure.

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Proportion of Participants With a Change of at Least 1 dB in Visual Field Mean Deviation and Pattern Standard Deviation
Tidsramme: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Percentage of participants whose visual field mean deviation and pattern standard deviation in the study eye improves by at least 1 dB, and percentage whose mean deviation and pattern standard deviation worsens by at least 1 dB, from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo).

Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in 24-2 Visual Field Mean Deviation (MD)
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Change in visual field mean deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean deviation is measured with Humphrey 24-2 SITA Standard and averaged across two reliable tests per visit.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 24-2 Visual Field Pattern Standard Deviation (PSD)
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Change in visual field pattern standard deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Pattern standard deviation is measured with Humphrey 24-2 SITA Standard and averaged across two reliable tests per visit.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 24-2 Visual Field Mean Light Sensitivity (MLS)
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Change in visual field mean light sensitivity (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean light sensitivity is obtained from Humphrey 24-2 SITA Standard testing and averaged across two reliable tests per visit.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 10-2 Visual Field Mean Deviation (MD)
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Change in visual field mean deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean deviation is measured with Humphrey 10-2 SITA Standard using one test per visit.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 10-2 Visual Field Pattern Standard Deviation (PSD)
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Change in visual field pattern standard deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Pattern standard deviation is measured with Humphrey 10-2 SITA Standard using one test per visit.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 10-2 Visual Field Mean Light Sensitivity (MLS)
Tidsramme: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Change in visual field mean light sensitivity (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean light sensitivity is obtained from Humphrey 10-2 SITA Standard testing using one test per visit.

Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

19. oktober 2026

Primær fullføring (Antatt)

1. april 2028

Studiet fullført (Antatt)

1. oktober 2028

Datoer for studieregistrering

Først innsendt

13. oktober 2026

Først innsendt som oppfylte QC-kriteriene

17. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • GLC 01-26
  • 588/FB/26 (Annen identifikator: Comitato Etico Territoriale Lazio Area 5)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared. Data ownership lies with the Sponsor (IRCCS Fondazione G.B. Bietti), and in accordance with the protocol and the EU General Data Protection Regulation (GDPR), study results will be disseminated only in anonymous and aggregated form through scientific publications.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere